Highlights
- 4DMedical shares rose 1.83% on 21 January 2026 after early morning declines.
- UC San Diego Health has begun clinical use of 4DMedical’s CT:VQ™ imaging technology, becoming the fourth U.S. academic medical center to adopt the system.
- 4DMedical completed a AUD 150 million institutional placement to support global commercial expansion and product deployment.
4DMedical Limited (ASX:4DX) closed at AUD 4.44 on 21 January 2026, up 1.83%, after recovering from early session losses. The Melbourne-based respiratory imaging company has delivered a 678.95% share price increase over the past year, driven by U.S.-focused commercial growth, strategic acquisitions, and institutional capital raising.
Who is 4DMedical?
Founded in Melbourne in 2013, 4DMedical develops structural and functional lung imaging technology for clinical applications. The company listed on the ASX in 2020 and expanded its U.S. presence through the December 2023 acquisition of Imbio, Inc., combining structural and functional image analysis expertise.
The company operates with an Australian-based engineering, research and development, and support team, while its revenue and go-to-market efforts are heavily U.S.-focused. 4DMedical currently holds over 100 patented technologies, nine FDA-cleared devices, and employs a global workforce of approximately 130 staff members. Its imaging solutions are distributed worldwide through established medical brands.
CT:VQ™ Launch at UC San Diego Health
On 7 January 2026, 4DMedical announced that UC San Diego Health, a leading U.S. academic medical center ranked consistently in the top 10 for Pulmonology and Lung Surgery, had commenced clinical use of CT:VQ™. UC San Diego Health is the fourth U.S. academic medical center to implement the technology, following Stanford, University of Miami, and Cleveland Clinic.
The deployment is structured under introductory pricing through March 2026, allowing early clinical adoption and workflow establishment before transitioning to full commercial terms. The four deployments were achieved within four months of FDA clearance, supporting 4DMedical’s commercialization strategy and demonstrating adoption in major U.S. healthcare centers.
Capital Raising Supports Growth
In addition to commercial milestones, 4DMedical recently completed a AUD 150 million institutional placement.






Please wait processing your request...